Table 1 Characteristics of studies included in the meta-analysis
Author | Year | Sample | Age, years | Weight, kg | Male% | SAPB | Control | Concomitant pain control | JADAD scale |
|---|---|---|---|---|---|---|---|---|---|
Okmen | 2018 | 20/20 | 53.5 ± 8.67/54.5 ± 7.92 | 75.25 ± 10.99/73.7 ± 10.4 | 55/50 | 20 ml of 0.25% bupivacaine | No block | PCA (tramadol) | 4 |
Kim | 2018 | 42/43 | 56.4 ± 8.7/54.7 ± 8.7 | 60.6 ± 10.3/63.4 ± 10.8 | 33.3/32.6 | 0.4 ml/kg of 0.375% ropivacaine | Normal saline | PCA (fentanyl) | 5 |
Park | 2018 | 42/42 | 58.0 ± 9.4/58.4 ± 10.5 | 63.8 ± 9.9/63.9 ± 12.0 | 40/43 | 30 ml of 0.375% ropivacaine | No block | PCA (fentanyl) | 5 |
Semynonov | 2019 | 47/57 | 62 ± 14.857/56.1 ± 17.83 | 72.3/71.8 | 44/29.8 | 2 ml/kg of 0.25% bupivacaine hydrochloride | No block | Standard pain management | 2 |
Lee | 2019 | 23/23 | 63.6 ± 9.9/65.1 ± 8.4 | 63.3 ± 12.3/61.7 ± 10.2 | 61/65 | 20 ml of 0.375% ropivacaine | No block | Standard pain management | 5 |
Chen | 2019 | 20/20 | 58.9 ± 5.7/57.1 ± 6.2 | 63.9 ± 7.8/62.3 ± 8.8 | 55/60 | 0.4 ml/kg of 0.25% ropivacaine | Local anesthetic infiltration | PCA (sufentanil) | 4 |
Viti | 2020 | 46/44 | 67.8 ± 9.3/71 ± 7.9 | - | 60.7/68.2 | 30 ml of 0.3% ropivacaine | No block | Standard pain management | 5 |
Shang | 2020 | 30/30 | 56.2 ± 7.2/58.23 ± 9.03 | - | 50/57 | 20 ml of 0.5% ropivacaine | Local anesthetic infiltration | PCA (butorphanol) | 5 |
Qiua | 2021 | 21/21/21 | 62.7 ± 8.1/63.0 ± 8.9/64.9 ± 8.3 | 62.4 ± 11.7/64.6 ± 7.4/60.8 ± 8.7 | 52.4/61.9/42.9 | 0.4 ml/kg of 0.375% ropivacaine | No block | PCA (sufentanil) | 4 |
Er | 2021 | 39/38 | 53.47 ± 11.63/52.36 ± 10.87 | - | 53.8/60.5 | 15 ml of 0.375% ropivacaine | No block | PCA (sufentanil) | 5 |
Dikici | 2022 | 30/30 | 53.2 ± 14.5/52.4 ± 14.3 | - | 46.7/46.7 | 0.25 ml/kg of 0.25% bupivacaine | Local anesthetic infiltration | PCA (morphine hydrochloride) | 3 |
Liu | 2022 | 44/44 | 59.16 ± 9.68/58.95 ± 9.64 | - | 63.6/59.1 | 20 ml of 0.375% ropivacaine | No block | PCA (sufentanil) | 3 |